Psychoplastogen Research Revival

Pipeline Innovation Review 2022 released by the EFPIA - European Federation of Pharmaceutical Industries and Associations analyses 8 innovation areas, including psychoplastogens: psychedelics like psilocybin, dissociatives - predominantly ketamine, and empathogens - MDMA. The review anticipates that psychoplastogens are expected to reach the market in short to mid-term and present a potential paradigm shift in our approach to treating some psychiatric disorders. It adds that they are “emerging as feasible, efficacious, and toxicologically safe treatments … and offer a novel approach to MDD care, which may replace the chronic use of anti-depressants and healthcare system resources. … Psychoplastogens may have profound and enduring impact on patients' quality of life, as well as families and caregivers … and nurture enduring equity-oriented care, deepen cultural connections, and decrease socioeconomic costs”. Find out more in the full review or see selection relevant to psychoplastogens.